# OnCo record rtx-2358 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rtx-2358/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rtx-2358" ;
  schema:name "[Ac-225]RTX-2358"@en ;
  schema:alternateName "RTX-2358"@en, "[177Lu]Lu-RTX-2358"@en ;
  schema:description "[Ac-225]RTX-2358 is an experimental small-molecule radioligand therapy from Ratio Therapeutics, in phase 1 trials for FAP-positive soft tissue sarcoma and FAP-positive metastatic non-small cell lung cancer."@en ;
  schema:url <https://onco.cc/drugs/rtx-2358/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://ratiotx.com/our-pipeline/>, <https://ratiotx.com/news1/>, <https://clinicaltrials.gov/study/NCT07689643>, <https://clinicaltrials.gov/search?intr=RTX-2358> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Small-molecule radioligand therapy (actinium-225; a lutetium-177 version is in an investigator study)" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/fap/> ;
  onco:companies <https://onco.cc/companies/ratio-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07156565/>, <https://onco.cc/trials/nct07689643/> .